Market News: Argentine President Milei met with Rio Tinto CEO Meloni in Rome.GCL Technology: It is estimated that there will be no more share repurchase cancellation in 2024. GCL Technology (03800) announced that in view of the fact that the photovoltaic industry is still in excessive competition, in order to ensure the stability of the company's operation and cope with the uncertainty in the future, the company expects that there will be no more share repurchase cancellation in the year ending December 31, 2024.Nearly 30 listed companies announced after-hours that their products would be selected, and the tenth batch of centralized drug procurement (centralized drug procurement) organized by the state was opened in Shanghai yesterday. According to incomplete statistics, as of press time, it includes Fuyuan Pharmaceutical, Yifan Pharmaceutical, ST Tiansheng, Hokuriku Pharmaceutical, Haizheng Pharmaceutical, Zhongheng Group, Yuandong Bio, Kelun Pharmaceutical, China Resources Shuanghe, Sinopharm Modern, Lingkang Pharmaceutical, Xuantai Pharmaceutical, Jiuzhou Pharmaceutical, Kang Enbei, Laimei Pharmaceutical, Kanghong Pharmaceutical, Huasen Pharmaceutical, Borui Pharmaceutical, Xianzeng Pharmaceutical. Among them, Kelun Pharmaceutical announced that 12 kinds of drugs, such as sodium acetate Ringer injection, sodium bicarbonate Ringer injection and gliclazide tablets, were to be selected.
During the battle of AI glasses, several new financings were under way in the field of AI glasses, among which Viture, which focuses on AR game scenes, and Even Realities, whose current product form is mainly a combination of AI and AR, have entered the late stage of the transaction, and their latest valuations both exceed 100 million US dollars. It is understood that Wang Huiwen, co-founder of Meituan, also recently invested in Viture. The old shareholders of this company founded in 2021 include Lanchi Venture Capital, BAI Capital and Zhenzhi Venture Capital. (latepost)Zhuhai Guanyu: It was selected as the designated supplier of low-voltage lithium batteries for its 12V cars after being notified by domestic car companies. Zhuhai Guanyu announced that the company was recently notified by a domestic car company and was selected as the designated supplier of low-voltage lithium batteries for its 12V cars. This appointment will help to enhance the company's competitiveness and sustainable development ability in this field, and lay the foundation for future market share enhancement. At present, the company has been recognized by many well-known car companies, such as SAIC, Zhiji, Jaguar Land Rover, Stellantis, GM, etc., and has obtained a number of vehicle project designation letters. However, the fixed-point notice is not the final supply agreement, and the project needs to go through many links from fixed-point to mass production, so it is uncertain whether the order can be obtained in the end.There is an urgent need for compound talents in the sustainable financial industry, so Gao Jin launched the sustainable financial curriculum system. On December 12th, at the "2024 China Sustainable Investment Development Forum", Shanghai Institute of Advanced Finance of Shanghai Jiaotong University first launched the sustainable financial curriculum system, becoming the first domestic university to build a special talent training system for the sustainable financial industry. Wang Tan, Vice President Gao Jin, Professor of Finance and Director of the Academic Committee of the Research Center for Sustainable Investment, said that the existing curriculum system of universities at home and abroad has many problems, such as low number, low matching degree and insufficient core courses. The sustainable financial industry is in urgent need of compound talents with relevant background of sustainable development and financial knowledge. According to Wang Tan, the current curriculum system of high-quality sustainable finance is still a basic version, and it will be continuously adjusted, optimized and improved according to industry trends and market demand in the future, so as to cultivate talents who are in short supply and meet market demand better. The Research Report on China Carbon Market System was released on the same day. The report makes an in-depth study on the future development of China's carbon market system and puts forward forward forward forward-looking suggestions. For example, the current national carbon market is still in the early stage of development, and it is suggested that the future national carbon market should focus on system design, basic capacity building, and the degree of marketization in line with the international carbon market. (The Paper)
On December 13th, Jiangsu Securities Regulatory Bureau issued an announcement that Yan Zhen had privately accepted the entrustment of customers to buy and sell securities during his tenure in the securities business department of Xuzhou Jianguo West Road of CITIC Securities (formerly known as the securities business department of Xuzhou Jiefang South Road of CITIC Securities). In violation of regulations, she was supervised to issue a warning letter and recorded it in the integrity file of the securities and futures market.Peng Qinghua met with Babacov, Vice Chairman of Russian State Duma, and Peng Qinghua, Vice Chairman of the National People's Congress Standing Committee (NPCSC), met with Babacov, Vice Chairman of Russian State Duma, in Beijing on the 13th. The two sides indicated that they will jointly implement the important consensus reached by the two heads of state, make good use of the platform of the joint working group of the Sino-Russian Parliamentary Cooperation Committee, deepen exchanges and cooperation between legislative bodies, and promote the further development of China-Russia comprehensive strategic partnership of cooperation in the new era. (Xinhua News Agency)Huabei Pharmaceutical Co., Ltd.: Four kinds of drugs under the company are planned to be selected for national centralized drug procurement. Huabei Pharmaceutical announced that the company and its subsidiary Xiantai Company participated in the tenth batch of national centralized drug procurement, and all four varieties are planned to be selected, including penicillin sodium for injection, piperacillin sodium for injection, ampicillin sodium for injection and sulbactam sodium for injection. The price of the drug to be selected this time has decreased compared with the original sales price. In 2023, the sales income of penicillin sodium for injection was 129 million yuan, accounting for 1.28% of the annual operating income. If the bid is confirmed and the purchase and sale contract is signed, the company will fully guarantee the supply according to the demand of the selected area, and promote the increment of related products in the selected area and the development of the off-standard market.
Strategy guide
12-14
Strategy guide 12-14
Strategy guide 12-14